| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1994;58:1574-1579
© 1994 The Society of Thoracic Surgeons
General Thoracic Surgical Unit, Division of Medical Oncology, and Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts USA
* Address reprint requests to Dr Wright, Warren 1212, Massachusetts General Hospital, Boston, MA 02114.
Between 1980 and 1988, 91 patients with adenocarcinoma of the esophagus were treated by surgical resection and selective postoperative therapy. Operative mortality was 2%. Pathologic stage was I in 4, II in 26, and III in 61. Actuarial 2- and 5-year survival was 24% and 8%. From 1987 to 1989, 16 patients with adenocarcinoma of the esophagus were treated with two cycles of 5-fluorouracil and cisplatin followed by surgical resection. There was 1 complete response (6%), 5 partial responses (31%), and 10 with no response (63%). Twelve patients had resection. Pathologic stage was I in 1, II in 4, and III in 8. There was one chemotherapy-related death and one surgical death. Actuarial 4-year survival is 42%. From 1990 to 1993, 22 patients with adenocarcinoma of the esophagus were treated with two cycles of etoposide, doxorubicin, and cisplatin followed by surgical resection. There was 1 complete response (5%), 11 partial responses (50%), and 10 with no response (45%). Eighteen patients had resection. Pathologic stage was 0 in 1, II in 8, and III in 9. There were no treatment-related deaths. The actuarial 2-year survival is 58%. Conclusions are necessarily limited because the patients were not treated in a randomized fashion. These preliminary results with preoperative chemotherapy appear improved (p = 0.04 and p = 0.004, respectively) as compared with results from 1980 to 1988 without preoperative chemotherapy.
This article has been cited by other articles:
|
|
 |
|
  P. A.M. Heeren, P. L. Jager, F. Bongaerts, H. van Dullemen, W. Sluiter, and J. Th.M. Plukker Detection of Distant Metastases in Esophageal Cancer with 18F-FDG PET J. Nucl. Med., June 1, 2004; 45(6): 980 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Igaki, H. Kato, Y. Tachimori, H. Sato, H. Daiko, and Y. Nakanishi Prognostic evaluation for squamous cell carcinomas of the lower thoracic esophagus treated with three-field lymph node dissection Eur J Cardiothorac Surg, June 1, 2001; 19(6): 887 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. van de Ven, P. De Leyn, W. Coosemans, D. Van Raemdonck, and T. Lerut Three-field lymphadenectomy and pattern of lymph node spread in T3 adenocarcinoma of the distal esophagus and the gastro-esophageal junction{star} Eur J Cardiothorac Surg, June 1, 1999; 15(6): 769 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Wright, J. C. Wain, T. J. Lynch, N. C. Choi, M. L. Grossbard, R. W. Carey, A. C. Moncure, H. C. Grillo, and D. J. Mathisen INDUCTION THERAPY FOR ESOPHAGEAL CANCER WITH PACLITAXEL AND HYPERFRACTIONATED RADIOTHERAPY: A PHASE I AND II STUDY J. Thorac. Cardiovasc. Surg., November 1, 1997; 114(5): 811 - 816. [Abstract] [Full Text]
|
|
|
|
|
|
W. H. Steup, P. De Leyn, G. Deneffe, D. Van Raemdonck, W. Coosemans, and T. Lerut TUMORS OF THE ESOPHAGOGASTRIC JUNCTIONLong-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 85 - 95. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
